Kyla Grimshaw

Kyla Grimshaw currently serves as the Director of Biology at PharmEnable Therapeutics, focusing on developing targeted oral therapies for diseases with high unmet clinical needs. Previously, Kyla held the position of Director of Biology at Sentinel Oncology Limited, where Kyla contributed to the development of new therapeutics for cancer. Kyla also has experience as Head of Development Operations at Fluidic Analytics Ltd, Director at KMG Consulting Ltd, and held various roles at Horizon Discovery, including VP Research Operations and R&D Director, after leading Hypoxium Ltd as Research Director and Co-Founder. Earlier career roles include Senior Scientist at Astex Therapeutics and Senior Research Associate at Millennium Pharmaceuticals. Kyla holds a PhD in Pharmacology from the University of Cambridge and a BSc in Pharmacology from UCL.